Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ELVN
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 6,018 | $38.48 | $231.5K Sale | Form 4 ↗ |
| Oct 19, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 5,000 | $38.47 | $192.3K Sale | Form 4 ↗ |
| Sep 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 289 | $51.49 | $14.9K Sale | Form 4 ↗ |
| Sep 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 2,194 | $50.72 | $111.3K Sale | Form 4 ↗ |
| Sep 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 3,535 | $50.03 | $176.9K Sale | Form 4 ↗ |
| Sep 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 240 | $51.48 | $12.4K Sale | Form 4 ↗ |
| Sep 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 1,844 | $50.71 | $93.5K Sale | Form 4 ↗ |
| Sep 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 2,916 | $50.03 | $145.9K Sale | Form 4 ↗ |
| Aug 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 1,388 | $59.35 | $82.4K Sale | Form 4 ↗ |
| Aug 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 4,630 | $58.35 | $270.2K Sale | Form 4 ↗ |
| Aug 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 1,100 | $59.35 | $65.3K Sale | Form 4 ↗ |
| Aug 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 3,900 | $58.37 | $227.6K Sale | Form 4 ↗ |
| Aug 4, 2026 | Mika K. Derynck Director | ELVN Enliven Therapeutics, Inc. | Sale | 158,795 | $60.21 | $9.6M Sale | Form 4 ↗ |
| Jul 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 123 | $53.87 | $6,626 Sale | Form 4 ↗ |
| Jul 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 2,638 | $53.38 | $140.8K Sale | Form 4 ↗ |
| Jul 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 2,564 | $52.32 | $134.1K Sale | Form 4 ↗ |
| Jul 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 369 | $51.48 | $19.0K Sale | Form 4 ↗ |
| Jul 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 324 | $49.97 | $16.2K Sale | Form 4 ↗ |
| Jul 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 63 | $53.92 | $3,397 Sale | Form 4 ↗ |
| Jul 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 2,184 | $53.42 | $116.7K Sale | Form 4 ↗ |
| Jul 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 2,063 | $52.39 | $108.1K Sale | Form 4 ↗ |
| Jul 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 459 | $51.55 | $23.7K Sale | Form 4 ↗ |
| Jul 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 231 | $50.05 | $11.6K Sale | Form 4 ↗ |
| Jul 6, 2026 | Lori Anne Kunkel Director | ELVN Enliven Therapeutics, Inc. | Sale | 5,889 | $50.84 | $299.4K Sale | Form 4 ↗ |
| Jul 6, 2026 | Lori Anne Kunkel Director | ELVN Enliven Therapeutics, Inc. | Sale | 4,111 | $49.98 | $205.5K Sale | Form 4 ↗ |
| Jun 22, 2026 | Orbimed Advisors LLC 10% owner | ELVN Enliven Therapeutics, Inc. | Sale | 46,776 | $45.00 | $2.1M Sale | Form 4 ↗ |
| Jun 22, 2026 | Orbimed Advisors LLC 10% owner | ELVN Enliven Therapeutics, Inc. | Sale | 787,024 | $45.38 | $35.7M Sale | Form 4 ↗ |
| Jun 22, 2026 | Orbimed Advisors LLC 10% owner | ELVN Enliven Therapeutics, Inc. | Sale | 1,477 | $45.00 | $66.5K Sale | Form 4 ↗ |
| Jun 22, 2026 | Orbimed Advisors LLC 10% owner | ELVN Enliven Therapeutics, Inc. | Sale | 24,846 | $45.38 | $1.1M Sale | Form 4 ↗ |
| Jun 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 1,238 | $44.75 | $55.4K Sale | Form 4 ↗ |
| Jun 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 3,401 | $43.86 | $149.2K Sale | Form 4 ↗ |
| Jun 17, 2026 | Benjamin Hohl CHIEF FINANCIAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 1,379 | $42.79 | $59.0K Sale | Form 4 ↗ |
| Jun 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 1,133 | $44.74 | $50.7K Sale | Form 4 ↗ |
| Jun 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 2,599 | $43.87 | $114.0K Sale | Form 4 ↗ |
| Jun 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 1,268 | $42.83 | $54.3K Sale | Form 4 ↗ |
| Jun 15, 2026 | Orbimed Advisors LLC 10% owner | ELVN Enliven Therapeutics, Inc. | Sale | 272,322 | $45.02 | $12.3M Sale | Form 4 ↗ |
| Jun 15, 2026 | Orbimed Advisors LLC 10% owner | ELVN Enliven Therapeutics, Inc. | Sale | 9,086 | $45.02 | $409.1K Sale | Form 4 ↗ |
| Jun 5, 2026 | Lori Anne Kunkel Director | ELVN Enliven Therapeutics, Inc. | Sale | 354 | $35.82 | $12.7K Sale | Form 4 ↗ |
| Jun 5, 2026 | Lori Anne Kunkel Director | ELVN Enliven Therapeutics, Inc. | Sale | 1,867 | $35.36 | $66.0K Sale | Form 4 ↗ |
| Jun 5, 2026 | Lori Anne Kunkel Director | ELVN Enliven Therapeutics, Inc. | Sale | 7,779 | $34.28 | $266.7K Sale | Form 4 ↗ |
| May 18, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 223 | $41.21 | $9,190 Sale | Form 4 ↗ |
| May 18, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 1,302 | $40.25 | $52.4K Sale | Form 4 ↗ |
| May 18, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 3,475 | $39.53 | $137.4K Sale | Form 4 ↗ |
| Apr 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 2,441 | $48.06 | $117.3K Sale | Form 4 ↗ |
| Apr 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 2,419 | $47.39 | $114.6K Sale | Form 4 ↗ |
| Apr 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 140 | $45.81 | $6,413 Sale | Form 4 ↗ |
| Mar 25, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 40,000 | $35.10 | $1.4M Sale | Form 4 ↗ |
| Mar 17, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 5,000 | $27.76 | $138.8K Sale | Form 4 ↗ |
| Mar 10, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 10,129 | $30.19 | $305.8K Sale | Form 4 ↗ |
| Mar 9, 2026 | Helen Louise Collins CHIEF MEDICAL OFFICER | ELVN Enliven Therapeutics, Inc. | Sale | 29,871 | $30.02 | $896.7K Sale | Form 4 ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:40 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances